Table 1.
N = 152 | 100% | |
---|---|---|
Sex | ||
Men | 90 | 59.2% |
Women | 62 | 40.8% |
Age, years (median) | 61.59 ± 12.08 | |
Tumor location | ||
Rectum | 106 | 69.7% |
Left hemicolon | 17 | 11.2% |
Right hemicolon | 29 | 19.1% |
Serum CEA levela (n) | ||
0 | 99 | 65.1% |
1 | 37 | 24.3% |
2 | 16 | 10.5% |
Serum CA19‐9 levelb (n) | ||
0 | 121 | 79.6% |
1 | 16 | 10.5% |
2 | 15 | 9.9% |
Stage | ||
I | 15 | 9.9% |
II | 31 | 20.4% |
III | 28 | 18.4% |
IV | 78 | 51.3% |
Treatment of metastatic CRC (N = 78) | ||
No surgical treatment | 22 | 28.2% |
Surgical treatment for primary tumor | 32 | 41.0% |
Surgical treatment for primary and metastatic tumor | 24 | 30.8% |
Recurrencec(local and distant) | ||
No | 61 | 62.2% |
Yes | 37 | 37.8% |
Survival status | ||
Alive | 92 | 60.5% |
Death | 60 | 39.5% |
CEA: 0 < 5 ng/mL, >5 to <20 ng/mL, 2 > 20 ng/mL.
CA19‐9: 0 < 20 ng/mL, 1 > 20 to <50 ng/mL, 2 > 50 ng/mL.
Including metastatic patients who received the surgical treatment for primary and metastatic tumor.